| Literature DB >> 34833906 |
Ángela Moratalla1, Salvador Cotillas2, Engracia Lacasa3, Pablo Cañizares1, Manuel A Rodrigo1, Cristina Sáez1.
Abstract
The inefficiency of conventional biological processes to remove pharmaceutical compounds (PhCs) in wastewater is leading to their accumulation in aquatic environments. These compounds are characterized by high toxicity, high antibiotic activity and low biodegradability, and their presence is causing serious environmental risks. Because much of the PhCs consumed by humans are excreted in the urine, hospital effluents have been considered one of the main routes of entry of PhCs into the environment. In this work, a critical review of the technologies employed for the removal of PhCs in hospital wastewater was carried out. This review provides an overview of the current state of the developed technologies for decreasing the chemical risks associated with the presence of PhCs in hospital wastewater or urine in the last years, including conventional treatments (filtration, adsorption, or biological processes), advanced oxidation processes (AOPs) and electrochemical advanced oxidation processes (EAOPs).Entities:
Keywords: advanced oxidation processes; hospital urine; pharmaceuticals; wastewater
Mesh:
Substances:
Year: 2021 PMID: 34833906 PMCID: PMC8621562 DOI: 10.3390/molecules26226813
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Composition of HWW.
| Parameters | Units | Range | Compound | Units | Range |
|---|---|---|---|---|---|
| HCO3− | mg dm−3 | 0–85 | Saccharose | mg dm−3 | 0–30 |
| CO32− | 0–6 | Glucose | 0–30 | ||
| Cl− | 50–2000 | COD | mg O2 dm−3 | 300–420 | |
| SO42− | 4–70 | BOD5 | 187–304 | ||
| Ca2+ | 2–20 | pH | - | 7.0–7.5 | |
| K+ | 3–75 | Antibiotics | 0.0001–100 | ||
| Mg2+ | 2–4 | Analgesics and anti-inflammatories | mg dm−3 | 0.00013–40 | |
| Na+ | 25–1200 | Betablocker | 10–20 | ||
| S2− | 0–15 | Hypertensive | 10–20 | ||
| PO43- | 5–30 | Antidepressant | 0.00387–0.008 | ||
| NO3− | 0–10 | Anticonvulsants | 0.0006–0.005 | ||
| NH4+ | 10–70 |
| UCF mL−1 | 103–106 | |
| Urea | 10–1300 |
| 103–106 | ||
| Humic acid | mg dm−3 | 0–10 | Fecal coliforms | CFU mL−1 | 103–104 |
| Citric acid | 0–10 | Total coliforms | 105–107 |
Figure 1Publications related to the removal of PhCs in HWW and only hospital urine from 1970 to 2020.
Conventional processes for the removal of PhCs in HWW.
| Effluent | Technology | Operation Parameters | Target Drug | Concentration | % Elimination | Ref. |
|---|---|---|---|---|---|---|
| HWW | Electrocoagulation | Aluminium electrodes (61 cm2), monopole configuration. 1000 mA | Dexamethasone | 100 μg L−1 | ~30 (45 min) | [ |
| HWW | Adsorption | Porous activated carbons prepared with Caesalpinia ferrea. | Captopril | 25 mg L−1 | CFAC.0.5/89.63 (60 min) | [ |
| CFAC.1.0/95.96 (60 min) | ||||||
| CFAC 0.5 (ratio of 0.5:1.0 of ZnCl2/CF at 600 °C) | CFAC.1.5/97.67 (60 min) | |||||
| CFAC 1.0. (ratio of 1.0:1.0 of ZnCl2/CF at 600 °C) | 50 mg L−1 | CFAC.0.5/86.08 (60 min) | ||||
| CFAC.1.0/92.07 (60 min) | ||||||
| CFAC 1.5. (ratio of 1.5:1.0 of ZnCl2/CF at 600 °C) | CFAC.1.5/94.22 (60 min) | |||||
| HWW | Biological | Oxacillin | 16 mg L−1 | 100 (6 days) | [ | |
| HWW | Adsorption | Activated carbons derived from Brazil nutshells: | Acetaminophen | 40 mg L−1 | BNS1.0/98.29 (30 min) | [ |
| 80 mg L−1 | BNS1.0/96.38 (30 min) | |||||
| HWW | Biodegradation (Biological) | Dicloxacillin | 40 mg L−1 | 100 (52 h) | [ | |
| Microbial consortium ( | 100 (3.75 h) | |||||
| HWW | Adsorption | Activated carbon filters with different concentrations of kenaf: | Paracetamol | 120 mg L−1 | K-36-500/~42 (1000 min) | [ |
| HWW | Adsorption | Sawdust adsorbent modified. Adsorbent dose 3.6 g L−1 and pH 8.3 | Tetracycline | ~0.25 mg L−1 | ~100 (53 min) | [ |
| HWW | Adsorption | Activated carbons with | Amoxicillin | 30 mg L−1 | CCP.600/98.01 (30 min) | [ |
| 60 mg L−1 | CCP.600/97.28 (30 min) | |||||
| HWW | Adsorption | Magnetic adsorbent was prepared from Olive kernel (MA-OK). Adsorbent dose = 0.5 g L−1, pH = 6 | Amoxicillin | 200 mg L−1 | 95.31 (90 min) | [ |
| 300 mg L−1 | 89.81 (90 min) | |||||
| 400 mg L−1 | 97.90 (90 min) | |||||
| HWW | Electrocoagulation | Three aluminium plates anodes and three iron plates cathodes. | Cefazolin | 0.0423 mg L−1 | 94 (30 min) | [ |
| HWW | Electrocoagulation | Two aluminium plate electrodes at 12.5 mA cm−2; pH = 7.78 | Ciprofloxacin | 154 μg L−1 | 100 (20 min) | [ |
| HWW | Electrocoagulation-persulfate | Two aluminium anodes and two aluminium cathodes at 2.75 mA cm−2; pH = 7. PS concentration of 0.84 mM | Ciprofloxacin | 3.5 mg L−1 | 81 (40 min) | [ |
| HWW | Electrocoagulation-adsorption | Aluminium electrodes at pH 7.8, 15.5 mA cm−2, 0.7 g L−1 chitosan | Cefazolin | 60 mg L−1 | 100 (23 min) | [ |
| Urine | Nanofiltration | Stainless steel dead-end stirred cell with an area of 54 cm2: | Paclitaxel | 0.5 mg L−1 | Desal 5 DK | [ |
| NF270 |
Figure 2Evolution of oxacillin concentration and antibacterial activity (AA) as a function of the operating time during the biological degradation process by Leptosphaerulina sp. Reprinted with permission from ref. [20]. Copyright 2018 Elsevier.
AOPS for the removal of PhCs in HWW.
| Effluent | Technology | Operation Parameters | Target Drug | Concentration | % Elimination | Ref. |
|---|---|---|---|---|---|---|
| HWW | Catalytic Ozonation | 37.5 mg O3/min | Meropenem | 6 mg L−1 | 100 (11.7 min) | [ |
| HWW | H2O2/Fe-Mn binary oxide | [H2O2]0 = 6.0 mM, 2.0 g L−1 of Fe-Mn binary oxide | Sulfamethoxazole | 0.1 mg L−1 | 100 (10 min) | [ |
| 1.6 mg L−1 | 92.8 (10 min) | |||||
| HWW | H2O2/magnetite | [H2O2] = 25 ppm; [Magnetite] = 1 g L−1; pH0 = 5; T = 25 °C. | Sulfamethoxazole | 5 mg L−1 | ~30 (240 min) | [ |
| Urine | Photo-Fenton | Simulated solar light at constant UVA intensity of 30 W m−2. 20 ppm Fe2+, pH = 3. [H2O2]0 = 400 mg L−1 (replenished when it dropped below 100 mg L−1). Two types of urine: diluted 1:10 and undiluted. | Iohexol | 600 mg L−1 | Diluted urine ~95 (120 min) | [ |
| 6000 mg L−1 | Undiluted urine ~48 (360 min) | |||||
| HWW | Solar Photo-Fenton | [H2O2]0 = 25 mg L−1, multiple addition of iron = 10 mg L−1 and pH = 5.0. | Anastrozole | 50 μg L−1 | ~50 (120 min) | [ |
| HWW | Solar Photo-Fenton and adsorption | Solar Photo Fenton process: three Fe2+ additions (5 mg dm−3 Fe2+ each and 150 mg dm−3) | Flutamide and transformation products | 500 μg L−1 | Solar Photo-Fenton: 58 (120 min) | [ |
| HWW | UV/H2O2 | Photo-oxidation process. UV254 lamp (15 W), [H2O2]0 = 25 mg L−1 | Metoprolol | 2.0 μg L−1 | 71.6 (10 min) | [ |
| Metoprolol acid | 2.0 μg L−1 | 88.7 (10 min) | ||||
| HWW | UV (275 nm)/ | Glass reactor with magnetic stirrer. UV-LED of 275 nm. [Free available chlorine] = 15 mg L−1, pH = 7 | Ciprofloxacin | 10 mg L−1 | 100 (60 min) | [ |
| HWW | TiO2-photocatalysis | Laboratory-scale photoreactor. UV lamp (365 nm) = 125 W. pH 7.6, TiO2 dosage is 563 mg L−1 | Metformin | 10 mg L−1 | 98 (150 min) | [ |
| Amoxicillin | 10 mg L−1 | 90 (150 min) | ||||
| Urine | TiO2-photocatalysis | [TiO2]: 0.5 g L−1, pH: 6.1, UVA light: 75 W | Losartan | 43.38 μmol L− | ~35 (20 min) | [ |
| Urine | UV/Persulfate | [PS] = 500 μmol L−1, pH = 6.1, UVC light: 60 W. | Losartan | 43.38 μmol L−1 | ~35 (20 min) | [ |
| HWW | Nano-photocatalysis | ZnO concentration on the plat: 0.6 g L−1. pH = 11, reaction time 90 min. | Ciprofloxacin | 3 mg L−1 | 90.25 (90 min) | [ |
| HWW | Thermally activated persulfate | Sodium persulfate = 10 mM, phosphate buffer = 50 μM. 20 mL, pH = 7.5, T = 70 °C. | Naproxen | 50 μM | ~100 (10 min) | [ |
| HWW | UV/H2O2 and biological process | Photo-oxidation process: Immersion-type photo-reactor. UV lamp (15 W), [H2O2]: 15 mg L−1 with a reaction time of 10 min. | Metoprolol | 2.0 μg L−1 | Bioreactor-UV/H2O2 | [ |
Figure 3Evolution of SMX upon CWPO with magnetite in different real aqueous matrices ([SMX]0 = 5 mg L−1; [H2O2]0 = 25 mg L−1; [magnetite]0 = 1 g L−1; pH0 = 5; T = 25 °C). Experimental (symbols) and model fit (solid lines). Reprinted with permission from ref. [47]. Copyright 2018 Elsevier.
Figure 4Schematic diagram of UV-LED reactor. Reprinted with permission from ref. [52]. Copyright 2020 Elservier.
Figure 5Evolution of naproxen concentration as function of the elapsed time during the treatment of hospital effluents. [NAP]0 = 50 μÌM, pH 7.50, T = 70 °C. Reprinted with permission from ref. [56]. Copyright 2015 Elsevier.
EAOPS for the removal of PhCs in HWW.
| Effluent | Technology | Operation Parameters | Target Drug | Concentration | % Elimination | Ref. |
|---|---|---|---|---|---|---|
| HWW | Electrooxidation | Two circular mesh anodes (Nb/BDD)/cathodes (Ti) at 35.4 mA cm−2. Flowrate: 1 L min−1 | Caffeine | 93 µg L−1 | >50 (120 min) | [ |
| Dihydrocabamazenine | 4.9 µg L−1 | |||||
| Desvenlafaxine | 8 µg L−1 | |||||
| Sulfamethoxazole | 3 µg L−1 | |||||
| Venlafaxine | 3.87 µg L−1 | |||||
| 2-Hydroxy Ibuprofen | 69 µg L−1 | |||||
| Carbamazepine | 0.62 µg L−1 | |||||
| 4-Hydroxy Diclofenac | 0.13 µg L−1 | |||||
| Diclofenac | 0.16 µg L−1 | |||||
| Ibuprofen | 20 µg L−1 | |||||
| Clarithromycin | 0.06 µg L−1 | |||||
| HWW | Electrooxidation | Flow-through electrochemical cell. BDD electrodes layer at 0.9 and 3.1 A and 50 °C | Iopromide | 0.5 or | 0.5 mg L−1-0.9 A: ~32/95/99/87 | [ |
| Urine | Electrooxidation | BDD anodes with boron content of 100, 200, 1300, 2500 and 8000 ppm and stainless steel (cathode) | Penicillin G | 50 mg L−1 | BDD100/98.03 at 6.4 Ah dm−3 | [ |
| Urine | Electrooxidation | Single compartment | Penicillin G | 100 mg L−1 | BDD: 100.00 (10 mA cm−2; 2.60 Ah dm−3)/100.00 (100 mA cm−2; 1.54 Ah dm−3) | [ |
| Urine | Electrooxidation | Pair of platinum-based iridium oxide composite electrodes at 1 A. The urine was diluted 2-fold, 4-fold and 8-fold. | Methotrexate | 880.2 μM | 2-fold/98.66 (4 h) | [ |
| Urine | Electrooxidation | Anodic oxidation-H2O2. Three types of anodes. BDD, Pt and IrO2. Cathode: carbon-PTFE air diffusion electrode, pH = 3 at 33.3 mA cm−2 | Captopril | 0.23 mM | BDD anode:100.00 (60 min) | [ |
| Urine | Solar | A solar planar pre-pilot flow plant. Anode: Pt plate. Cathode: carbon-PTFE air diffusion electrode. | Captopril | 0.23 mM | Urine 1: | [ |
| Urine | Electrooxidation | One-compartment filter-press flow cell. Flow rate: 460 mL min−1. | Tetracycline | 200 mg L−1 | 10 mA cm−2: | [ |
| Urine | Electrooxidation | MMO-Ti/RuO2-IrO2 anode and zirconium spiral (cathode) at 4.0 mA cm−2 | Cephalexin | 86.0 μM | ~100.00 (2 h or 0.43 Ah dm−3) | [ |
| Urine | Electrooxidation | BDD with 500 ppm of boron (Diacell cell) at 20, 50 and 100 mA cm−2. Flow rate: 6.67 mL s−1. Urine in methanol. | 17-β Estradiol | 10 mg L−1 | 20 mA cm−2: 100~7 Ah dm−3 | [ |
| Urine | Electrooxidation | Single compartment electrochemical cell. BDD anode with boron content of 500 ppm at 100 and 1000 A m−2 | Ibuprofen | 10 mg L−1 | 100 A m−2: Ibuprofen/100~32 Ah dm−3; Cloxacillin/100 18 Ah dm−3 | [ |
| HWW | Electrooxidation | Ti/IrO2 rectangular (anode) and zirconium spiral (cathode). pH = 6.5 at 5 mA cm−2 | Cephalexin | 40 µM | ~60 (30 min) | [ |
| Urine | Electrooxidation | Undivided cell equipped with a Ti/IrO2 anode and a zirconium spiral cathode. pH = 6.0 and 5 mA cm−2 | Naproxen | 40 µM | 20 (60 min) | [ |
| Urine | Electrooxidation | MMO-Ti/IrO2 anode and Titanium cathode at 6.53 mA cm−2 | Norfloxacin | 125.0 μM | ~65 (180 min) | [ |
| Urine | Electrooxidation | Undivided cell. Pt sheet was used as anode and a glassy carbon was used as cathode. Current density range: 0.5–150.0 mA cm−2 | Cefazolin | 100.0 μM | 0.5 mA cm−2: | [ |
| Urine | Electrooxidation | A platinum net was used as anode and reticulated nickel foam electrode was used as cathode and. V: 1 V | Iomeprol | 0.1 mM | 100 (120 min) | [ |
| Urine | Electrooxidation | Single compartment electrochemical cell. BDD anode and stainless steel (cathode) at 1.25, 2.5 and 5 mA cm−2. MMO-RuO2 anode and stainless steel (cathode) at 1.25, 2.5 and 5 mA cm−2. | Chloramphenicol | 100 mg L−1 | BDD at 1.25 mA cm−2/100 (8 Ah dm−3) | [ |
| HWW | MBR-Electrooxidation | Submerged membrane bioreactor (MBR) in continuous mode. Electrooxidation reactor in discontinuous mode. Nb/BDD anode at 0.5 A. | Carbamazepine | 10 µg L−1 | MBR-EO | [ |
| HWW/urine | Electro-Fenton | BDD anode, 3D-Carbon-felt (cathode), 0.1 mM Fe2+ pH: 3 at 4.17 mA cm−2 | Piroxicam | 25.6 mg L−1 | 100 (120 min) | [ |
| HWW | Electro-Fenton | Two iron plate electrodes. 2.75 pH solution, 122.5 μL L−1 H2O2 and 8 mA cm−2 | Acetaminophen | 1.35 mg L−1 | 100 (10 min) | [ |
| Urine | Electro-Fenton | Microfluidic Flow-Through reactor. Pressurized system. 3D-MMO-IrO2Ta2O5 anode and modified 3D-titanium mesh with CB/PTFE cathode, pH 3, 5 mA cm−2, and 10.8 g goethite (heterogeneous catalyst). | Meropenem | 50 mg L−1 | 0 bar: 80.60 | [ |
| Urine | Electrooxidation and | Microwave-made MMO-Ti/RuO2IrO2 anode and stainless steel (cathode). BDD anode with a boron content of 200 ppm and stainless steel (cathode). Current density: 30 mA cm−2. UVC lamp 9W in photo-electrooxidation. | Penicillin G | 50 mg L−1 | EO-MMO: | [ |
| Urine | Electro-Fenton or photo Electro-Fenton | Two different anode: 200 ppm BDD and a MMO- Ti/Ru0.5Ir0.5O2. Cathode: modified carbon felt. 120 mA. 0.5 mM of Fe2+, pH 3 and a 9W UVC lamp for the PhEF tests | Penicillin G | 50 mg L−1 | EF-MMO: | [ |
| Urine | Electrooxidation and | Two experimental configurations: | Penicillin G | 50 mg L−1 | Conventional stirred-tank: | [ |
Figure 6Mechanisms expected for the photo-electrolytic reclamation of secondarily treated wastewater. Reprinted with permission from ref [98]. Copyright 2016 Elsevier.
Figure 7Main electrochemical degradation pathway of norfloxacin in presence of chloride ions. Reprinted with permission from ref. [87]. Copyright 2017 Elsevier.
Figure 8Evolution of chloramphenicol as a function of the applied electric charge during the electrochemical oxidation of 100 mg dm−3 CAP in urine media. Current density: (■, □) 1.25 mA cm−2; (▲, ∆) 2.5 mA cm−2; (●, ○) 5 mA cm−2. Anodic material: (black symbols) BDD; (white symbols) MMO. Reprinted with permission from ref [90]. Copyright 2020 Elservier.
Figure 9Mechanisms expected in the electro-Fenton process. Reprinted with permission from ref [102]. Copyright 2021 Elsevier.
Figure 10Degradation of piroxicam in different matrices. Experimental conditions: [Piroxicam] = 0.08 mM; [Na2SO4] = 0.05 M; [Fe2+] = 0.10 mM; I = 100 mA (4.17 mA cm−2); V = 0.25 L; pH = 3.0 and room temperature. Reprinted with permission from ref. [92]. Copyright 2019 Elservier.
Figure 11Influence of the aqueous matrix on the normalized captopril concentration decay during the SPEF treatment of 2.5 L of 0.230 mM drug solutions with 0.50 mM Fe2+ at pH 3.0 and 35 °C using a solar pre-pilot flow plant with a Pt/air-diffusion cell at j = 50 mA cm−2 and liquid flow rate of 180 L h−1. Matrix: (▲) Urban wastewater, (■) urine 1 (13.9 mM urea + 0.073 mM uric acid + 0.367 mM creatinine), (●) urine 2 (27.8 mM urea + 0.146 mM uric acid + 0.734 mM creatinine) and (▼) urine 3 (55.6 mM urea + 0.292 mM uric acid + 1.47 mM creatinine). The inset panel shows the kinetic analysis of the above concentration decays assuming a pseudo-first-order reaction. Reprinted with permission from ref. [80]. Copyright 2020 Elsevier.